Company intelligence / Profile preview

MAIA Biotechnology, Inc.

Chicago, Illinois, United Statesmaiabiotech.com ↗

Ownership: Public · MAIA
Development stage: Phase 2

Overview

The THIO-101 Phase 2 trial has shown promising results with median overall survival in third-line treatment reaching 16.9 months. The treatment has been generally well-tolerated in heavily pre-treated populations. The company is expanding its Phase 2 trial and planning to start a Phase 3 trial in H2 2025[9].

Therapeutic areas: Oncology
Modalities: Small molecules
Industry: Biotech

Drug pipeline

3 assets

ateganosine

2 more assets in the full pipeline.

Partnerships

Regeneron (clinical supply agreement for Libtayo®)

Financials

Market cap: $64.2M
Total revenue: $0
Enterprise value: $36.6M

Beyond the preview

Go deeper on MAIA Biotechnology, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MAIA Biotechnology, Inc..